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Biomarker-guided treatment is a rapidly developing area of medicine, where treatment choice is 
personalised according to one or more of an individual’s biomarker measurements. A number of 
biomarker-guided trial designs have been proposed in the past decade, including both adaptive and 
non-adaptive trial designs which test the effectiveness of a biomarker-guided approach to treatment 
with the aim of improving patient health. A better understanding of them is needed as challenges 
occur in terms of trial design, analysis and practical application, including the control of the false-
positive rate, power of the study, prevalence of the biomarker, treatment effect estimation and the 
potential increases in cost and time. We have undertaken a comprehensive literature review based 
on an in-depth search strategy with a view to providing the research community with clarity in 
definition, methodology and terminology of the various reported biomarker-guided trial designs 
from a total of 211 included papers. Of these 211 included papers, 107 papers related to biomarker-
guided adaptive trial designs were reviewed in our published paper Antoniou et al. (2016) [1]; 
biomarker-guided non-adaptive trial designs were referred to in 100 papers  and are reviewed in our 
more recent paper to be published shortly.  
 
Navigating the literature to gain an understanding of which trial design to implement in a given 
situation, and the practical implications of doing so is difficult as our reviews revealed. Hence, in 
order to improve the understanding of the biomarker-guided trial designs and provide valuable and 
much-needed guidance on their implementation we are developing a user-friendly online tool 
(www.BiGTeD.org) informed by our literature review. BiGTeD will provide an easily accessible 
resource to inform on the most optimal design when embarking on a biomarker-guided trial 
including easy to navigate graphical displays of the various trial designs. Knowledge on how to 
design, implement and analyse these trials is essential for testing the effectiveness of a biomarker-
guided approach to treatment. Hence, in this study, we focus on key statistical aspects of several of 
the identified trial designs with particular focus on examining the sample size requirement under 
different settings where outcome is time-to-event. To achieve this, we applied statistical simulation 
methods and here we report on our findings. 
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